Eltrombopag: a medical countermeasure to mitigate thrombocytopenia following myelosuppressive doses of radiationsee statement of work for more details

Ended Definitive Contract Awarded Last action

Contract number
HHSO100201700026C
Awardee
Awarding agency
Obligated
$16,334,775

Award facts

Contract value 40% obligated
  • $16,334,774.81 Current, with exercised options
  • $41,003,238.81 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
East Hanover, NJ 07936, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00013 · The purpose of this modification is to deobligate cancelling funds in the amount of $2,539,496.23 as follows: -$2,539,496
Other Administrative Action P00011 · This unilateral modification is to deobligate cancelling funds on clin 00001. -$18,841,773
Other Administrative Action P00010 · This no cost modification is to change the contracting officer from jonathan gonzalez to erin greninger. Accordingly, under section G.1. Contracting officer,… $0
Other Administrative Action P00009 · The purpose of this unilateral modification is to update the contracting officer: a.) the contracting officer is changed from tatricia james to jonathan… $0
Other Administrative Action P00008 · Revise clin 0004 $7,393,435
Other Administrative Action P00007 · Contractor requested a NCE through 6/1/2023 due to delays caused by the COVID19 pandemic. $0
Funding Only Action P00006 $2,910,000
Change Order P00005 · To develop eltrombopag via the animal rule for the treatment of hematopoietic sub-syndrome of acute radiation syndrome (H-ARS) during the field care phase of… $1,992,113
Supplemental Agreement for work within scope P00004 · MOD 4 supplemental funding for assay and non-clinical studies. Changes CO. $635,815
Supplemental Agreement for work within scope 3 $0
Supplemental Agreement for work within scope 2 $197,202
Supplemental Agreement for work within scope 1 $696,735
Original award $23,890,744
Show all 13

About this award

The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Novartis Pharmaceuticals Corporation for eltrombopag, a medical countermeasure to mitigate thrombocytopenia following myelosuppressive doses of radiation, with a ceiling value of $41.0 million and an ultimate completion date of May 22, 2026. This is a firm fixed-price contract with no set-aside.

Place of performance is East Hanover, NJ. The award originated on September 14, 2017. A recent modification deobligated $2.5 million across multiple contract line items, reflecting budget management within the performance window.

In FY2021, the contract reported $2.9 million invoiced against 0.7 FTEs and 1,373 contractor hours, generating a derived government-paid rate of $2,140.52 per hour. The prime self-performed all reported labor with no subcontractors.

Quick answers

Who was awarded contract HHSO100201700026C?

HHSO100201700026C was awarded to Novartis Pharmaceuticals Corporation by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 14, 2017.

How much is contract HHSO100201700026C worth?

The government has obligated $16,334,775 on HHSO100201700026C. Its potential value, with all options, is $41,003,239.

Was contract HHSO100201700026C competed?

The extent of competition for HHSO100201700026C was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award